Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 366

Sort by

Sort Order Select

Journal Articles

Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs

Blood blood.2025029572.

https://doi.org/10.1182/blood.2025029572

Published: 2025

Includes: Supplemental data

Journal Articles

Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myeloma

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panos Malandrakis, Despina Fotiou, Nikolaos Kanellias, Magdalini Migkou, Dr, Foteini Theodorakakou, Vasiliki Spiliopoulou, Irene Solia, Evangelos Eleutherakis-Papaiakovou, Giorgos Psarros, Efstathios Kastritis, Meletios A Dimopoulos

Blood blood.2025031629.

https://doi.org/10.1182/blood.2025031629

Published: 2025

Includes: Supplemental data

Journal Articles

Validation of the new ims/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients

Efstathios Kastritis, Maria Gavriatopoulou, Foteini Theodorakakou, Eirini Solia, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Nikolaos Kanellias, Evangelos Eleutherakis Papaiakovou, Magdalini Migkou, Vasiliki Spiliopoulou, Ilias Katsadouros, Stavroula Giannouli, Panagiotis Tsirigotis, Asimina Papanikolaou, Despina Fotiou, Konstantinos Giannakas, Erasmia Boutakoglou, Evangelos Terpos, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 923.

https://doi.org/10.1182/blood-2025-923

Published: 2025

Journal Articles

Hematologist based management of ocular adverse events using the VRA tool in newly-diagnosed myeloma patients, ineligible for ASCT who received belantamab mafodotin plus lenalidomide/dexamethasone: Updated results from the randomized part 2 of bela-rd Study

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Eirini Solia, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Ilias Katsadouros, Magdalini Migkou, Evangelos Eleutherakis Papaiakovou, Despina Fotiou, Helen Vassalou, Efstathios Kastritis, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 4038.

https://doi.org/10.1182/blood-2025-4038

Published: 2025

Journal Articles

Response-adapted randomization to Q2W vs Q4W isatuximab beyond cycle 6 in relapsed multiple myeloma: Results from a phase 2 Study of isa-pd in lenalidomide- and PI-exposed patients

Evangelos Terpos, Maria Gavriatopoulou, Vasiliki Lampropoulou, Emmanouil Spanoudakis, Eirini Katodrytou, Anastasia Sioni, Eleftheria Hatzimichael, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Eirini Solia, Nikolaos Kanellias, Helen Vassalou, Nikolaos Giannakoulas, Sosana Delimpasi, Maria Kotsopoulou, Efstathios Kastritis, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 4037.

https://doi.org/10.1182/blood-2025-4037

Published: 2025

Journal Articles

Isatuximab with bortezomib, cyclophosphamide, and dexamethasone followed by isatuximab and lenalidomide maintenance in newly diagnosed multiple myeloma patients with severe renal impairment: Final analysis of a phase 2 study by the greek myeloma study group

Evangelos Terpos, Efstathios Kastritis, Sosana Delimpasi, Maria Papathanasiou, Vasiliki Lampropoulou, Nikolaos Kanellias, Ioannis Ntanasis-Stathopoulos, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Evangelos Eleutherakis-Papaiakovou, Yagnik Vyas, Maria Kotsopoulou, Eirini Katodrytou, Maria Gavriatopoulou, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 4036.

https://doi.org/10.1182/blood-2025-4036

Published: 2025

Journal Articles

Plasma proteomic analysis as a tool for monitoring the development of ibrutinib resistance in Waldenström macroglobulinemia.

Tina Bagratuni, Ioannis Kollias, Christos Vlachos, Ourania Theologi, Alexandra Papadimou, Nefeli Mavrianou Koutsoukou, Christine-Ivy Liacos, Kostantina Taouxi, Katerina Chrisostomidou, Agisilaos Papadopoulos, Eleni Kalafati, Despina Fotiou, Evangelos Terpos, Meletios Dimopoulos, Efstathios Kastritis

Blood (2025) 146 (Supplement 1): 2154.

https://doi.org/10.1182/blood-2025-2154

Published: 2025

Journal Articles

Results of the promise study from ~30,000 individuals screened for monoclonal gammopathies

Blood (2025) 146 (Supplement 1): 403.

https://doi.org/10.1182/blood-2025-403

Published: 2025

Journal Articles

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

Blood (2025) 146 (Supplement 1): 4598.

https://doi.org/10.1182/blood-2025-4598

Published: 2025

Journal Articles

Multimodal epigenetic microarray classifies AML, MDS and controls using peripheral blood

Miriam Neaman, Jasline Deek, Rita Haldar, Yakir Moshe, Moshe Mittelman, Irit Avivi, Amit Manor, Mika Bell, Roy Vitkon, Mor Levi, Karolis Sablauskas, Efstathios Kastritis, Tomas Papajik, Eva Kriegova, Yuval Ebenstein

Blood (2025) 146 (Supplement 1): 3509.

https://doi.org/10.1182/blood-2025-3509

Published: 2025

Journal Articles

Health care professionals (HCPs) perspectives on treatment and management of light chain (AL) amyloidosis: An international cross-sectional survey study

Jamie Zigterman, Kristen Hsu, Phaedra Johnson, Efstathios Kastritis, Paolo Milani, Angela Dispenzieri

Blood (2025) 146 (Supplement 1): 7493.

https://doi.org/10.1182/blood-2025-7493

Published: 2025

Journal Articles

Incidence and risk factors for infections in the real-world setting in newly diagnosed myeloma patients treated with modern induction regimens

Efstathios Kastritis, Eirini Solia, Foteini Theodorakakou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Nikolaos Kanellias, Evangelos Eleutherakis Papaiakovou, Magdalini Migkou, Vasiliki Spiliopoulou, Ilias Katsadouros, Despina Fotiou, Stavroula Giannouli, Panagiotis Tsirigotis, Maria Gavriatopoulou, Evangelos Terpos, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 2228.

https://doi.org/10.1182/blood-2025-2228

Published: 2025

Journal Articles

Burden and characteristics of infections in patients treated with bispecific antibodies and the impact of immunoglobulin replacement

Efstathios Kastritis, Eirini Solia, Ilias Katsadouros, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Foteini Theodorakakou, Nikolaos Kanellias, Evangelos Eleutherakis Papaiakovou, Magdalini Migkou, Vasiliki Spiliopoulou, Despina Fotiou, Maria Gavriatopoulou, Evangelos Terpos, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 2227.

https://doi.org/10.1182/blood-2025-2227

Published: 2025

Journal Articles

Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival

Panagiotis Malandrakis, Ioannis Kostopoulos, Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Sotirios Manganas, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Vasiliki Spiliopoulou, Magdalini Migkou, Despina Fotiou, Foteini Theodorakakou, Efstathios Kastritis, Maria Gavriatopoulou, Ourania Tsitsilonis, Meletios Dimopoulos, Evangelos Terpos

Blood (2025) 146 (Supplement 1): 2216.

https://doi.org/10.1182/blood-2025-2216

Published: 2025

Journal Articles

Patient-derived amyloidogenic light chain triggers cardiovascular toxicity In Vivo and reveals ICAM-1 as a novel potential biomarker in patients with AL amyloidosis

Panagiota-Efstathia Nikolaou, Foteini Theodorakakou, Angelina Choustoulaki, Julie Courraud, Alexandros Briasoulis, Meletios Dimopoulos, Evangelos Terpos, Asimina Papanikolaou, Despina Fotiou, Efstathios Kastritis

Blood (2025) 146 (Supplement 1): 5751.

https://doi.org/10.1182/blood-2025-5751

Published: 2025

Journal Articles

Semaphorin 4D and interleukin 1beta-complement cascade axis are key drivers of disease progression in multiple myeloma

Ioannis Ntanasis-Stathopoulos, Panagiota-Efstathia Nikolaou, Charalampos Filippatos, Panagiotis Bakouros, Manousos Makridakis, Ioannis V. Kostopoulos, Christine-Ivy Liacos, Maria Frantzi, Panagiotis Malandrakis, Maria Gavriatopoulou, Antonia Vlahou, Efstathios Kastritis, Ourania Tsitsilonis, Meletios Dimopoulos, Evangelos Terpos

Blood (2025) 146 (Supplement 1): 3925.

https://doi.org/10.1182/blood-2025-3925

Published: 2025

Journal Articles

Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis

Blood (2025) 146 (Supplement 1): 4588.

https://doi.org/10.1182/blood-2025-4588

Published: 2025

Journal Articles

Circulating tumor cells (CTCs) combined with frailty index offer an improved stratification system for transplant-ineligible newly diagnosed multiple myeloma patients

Blood (2025) 146 (Supplement 1): 5791.

https://doi.org/10.1182/blood-2025-5791

Published: 2025

Journal Articles

Von willebrand factor levels show independent prognostic significance in patients with AL amyloidosis treated with daratumumab-based therapies

Foteini Theodorakakou, Zoey Kapsimali, Alexandra Papadimou, Katerina Chrisostomidou, Kostantina Taouxi, Ilias Katsadouros, Panagiotis Malandrakis, Magdalini Migkou, Eirini Solia, Ioannis Ntanasis-Stathopoulos, Vasiliki Spiliopoulou, Evangelos Eleutherakis Papaiakovou, Asimina Papanikolaou, Maria Gavriatopoulou, Evangelos Terpos, Eleni Pergantou, Meletios Dimopoulos, Ioannis Papassotiriou, Efstathios Kastritis

Blood (2025) 146 (Supplement 1): 2192.

https://doi.org/10.1182/blood-2025-2192

Published: 2025

Journal Articles

Characteristics and clinical course of younger Patients with early lesions in a contemporary cohort of 1240 patients: Low risk features and low risk of complications

Eirini Solia, Foteini Theodorakakou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Evangelos Eleutherakis Papaiakovou, Magdalini Migkou, Vasiliki Spiliopoulou, Ilias Katsadouros, Konstantinos Giannakas, Stavroula Giannouli, Panagiotis Tsirigotis, Asimina Papanikolaou, Despina Fotiou, Maria Gavriatopoulou, Evangelos Terpos, Meletios Dimopoulos, Efstathios Kastritis

Blood (2025) 146 (Supplement 1): 2191.

https://doi.org/10.1182/blood-2025-2191

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs

Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myeloma

Validation of the new ims/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients

Hematologist based management of ocular adverse events using the VRA tool in newly-diagnosed myeloma patients, ineligible for ASCT who received belantamab mafodotin plus lenalidomide/dexamethasone: Updated results from the randomized part 2 of bela-rd Study

Response-adapted randomization to Q2W vs Q4W isatuximab beyond cycle 6 in relapsed multiple myeloma: Results from a phase 2 Study of isa-pd in lenalidomide- and PI-exposed patients

Isatuximab with bortezomib, cyclophosphamide, and dexamethasone followed by isatuximab and lenalidomide maintenance in newly diagnosed multiple myeloma patients with severe renal impairment: Final analysis of a phase 2 study by the greek myeloma study group

Plasma proteomic analysis as a tool for monitoring the development of ibrutinib resistance in Waldenström macroglobulinemia.

Results of the promise study from ~30,000 individuals screened for monoclonal gammopathies

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

Multimodal epigenetic microarray classifies AML, MDS and controls using peripheral blood

Health care professionals (HCPs) perspectives on treatment and management of light chain (AL) amyloidosis: An international cross-sectional survey study

Incidence and risk factors for infections in the real-world setting in newly diagnosed myeloma patients treated with modern induction regimens

Burden and characteristics of infections in patients treated with bispecific antibodies and the impact of immunoglobulin replacement

Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival

Patient-derived amyloidogenic light chain triggers cardiovascular toxicity In Vivo and reveals ICAM-1 as a novel potential biomarker in patients with AL amyloidosis

Semaphorin 4D and interleukin 1beta-complement cascade axis are key drivers of disease progression in multiple myeloma

Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis

Circulating tumor cells (CTCs) combined with frailty index offer an improved stratification system for transplant-ineligible newly diagnosed multiple myeloma patients

Von willebrand factor levels show independent prognostic significance in patients with AL amyloidosis treated with daratumumab-based therapies

Characteristics and clinical course of younger Patients with early lesions in a contemporary cohort of 1240 patients: Low risk features and low risk of complications

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only